Page 1254 - Basic _ Clinical Pharmacology ( PDFDrive )

1240 Index

Sedative-hypnotic drugs (Cont.): Selexipag, 313b pharmacokinetics of, 540, 540t
pharmacokinetics of, 383–386 Self-monitoring of blood glucose, 753 preparations available, 551t
absorption and distribution, 383 Semustine, 953f Serotonin syndrome, 288, 288b, 288t, 549,
biodisposition in, factors in, 386 Senna, 1099 1042
biotransformation in Sensitivity, target organ, on target Serotonin transporter (SERT, SLC6A4)
barbiturates, 386 concentration, 52 description of, 95b
benzodiazepines, 384f, 384–385, Sensitization, opioid, 554 MDMA (ecstasy) on, 587
385t Sepsis, 343 Sertaconazole, 1072
newer hypnotics, 385t, 386 Septic shock, 343t, 343–344 Sertindole, 515
excretion in, 386 Sequential scheduling, in cancer Sertoli cells, 740
poisoning management for, 1041t, 1045 chemotherapy, 952 Sertraline, 540t, 542t, 546t, 549t. See also
in pregnancy, 383 Serenoa repens, 1141 Selective serotonin reuptake
preparations available, 394t Serotonin (5-HT), 285–292 inhibitors (SSRIs)
ramelteon, 382, 384b, 394t chemical structure of, 1102f SERT transporter, 8t
sedative actions of, 381 chemistry and pharmacokinetics of, Serum sickness drug reactions, 999–1000
tasimelteon, 382 285f, 285–286 Sevelamer, for hyperphosphatemia, 784
tolerance and dependence on, 389–390 clinical pharmacology of, 288–289 Sevoflurane, 441–449. See also Anesthetics,
toxicology of in CNS, 374f, 376t, 379 inhaled
direct toxic actions, 392 in depression, 534, 535f properties of, 443t
drug interactions in, 393 discovery of, 285 structure of, 443f
drug response alterations in, 392–393 functions of, 92t Sex (gender), in drug metabolism, 69
Sedative-hypnotics, 388 pharmacodynamics of, 286–288 Shape, drug, 4
Sedatives, 381 in schizophrenia, 512 Shivering, opioids for, 563
Seizures, 409. See also Epilepsy (Seizures); Serotonin (5-HT) receptor Short-bowel syndrome, 1113
specific seizure in CNS, 379 Sibutramine, 151, 289b
antipsychotics as cause of, 522 description of, 286, 286t Sickle cell disease, hydroxyurea and, 592b
atonic, 430 Serotonin (5-HT) receptor agonists, Sick sinus syndrome, 234b
case study on, 409, 439 289–291, 296t, 394t Side effect, 39. See also Adverse drug event
classification of, 409, 410t clinical pharmacology of, 288–289 (ADE)
drugs for, 309–439 migraine headaches and, 289–291, 290f, Signaling mechanisms, drug action and,
Selective estrogen receptor modulators 291t 26–35
(SERMs), 724, 737, 737f preparations available, 297t–298t cytokine receptors in, 28–29, 29f
for bone, 790t Serotonin 5-HT 4 receptor agonists, 1100 G proteins and second messengers in,
osteoporosis treated with, 780b, 786, 790t Serotonin (5-HT) receptor antagonists, 30f, 30–32, 31f
preparations available, 790t 291–292, 297t, 298t G proteins in, 31t
Selective serotonin reuptake inhibitors Serotonin 5-HT 3 receptor antagonists interplay among, 34–35
(SSRIs), 546t, 549t. See also antiemetic, 1103–1105, 1116t, 1117t intracellular receptors for lipid-soluble
Antidepressant agents irritable bowel syndrome treated with, agents in, 27, 27f
adverse effects in, 546–547 1102, 1102f ligand- and voltage-gated channels in,
discontinuation syndrome associated Serotonin (5-HT) receptor modulators, 29f, 29–30
with, 547 for depression, 550t. See also of ligand-regulated transmembrane
dosing of, 546t Antidepressant agents enzymes, 27–28, 28f
drug interactions in, 548, 548t, 1172t chemistry of, 538 mechanisms of, transmembrane, 26, 26f
pharmacodynamics of, 541–543, 542t clinical pharmacology of phosphorylation in, 35
pharmacokinetics of, 539–540, 540t adverse effects in, 547 receptor regulation in, 32, 33f
preparations available, 551t drug interactions in, 548–549 receptor tyrosine kinases in, 27–28, 28f
teratogenicity of, 547 pharmacodynamics of, 542t, 543 second messengers in
Selectivity, drug pharmacokinetics of, 540t, 541 cAMP, 32, 34, 34f
in beneficial vs. toxic effects, 39–40 preparations available, 551t cGMP, 34, 343f
definition of, 39 Serotonin-norepinephrine reuptake phosphoinositides and calcium,
in structurally identical receptors, 27f, 35 inhibitors (SNRIs), 550t 32–34, 34f
Selegiline chemistry of, 536 Sildenafil, 34, 200b
depression treated with, 540t, 541, 546t, clinical pharmacology of Silodosin, 160
550t adverse effects in, 547 Siltuximab, 994
parkinsonism treated with, 498f, 499, drug interactions in, 548 Silver nitrate, 901
508t description of, 537 Silver sulfadiazine, 836, 901
structure of, 495f dosing of, 546t Silybum marianum, 1138–1139
Selepressin, 308 pharmacodynamics of, 542, 542t Simeprevir, 890–891